Implementation and evaluation of Australian pharmacists' diabetes care services

Journal of the American Pharmacists Association

Volumn 44, Issue 4, 2004, Pages 455-466

  Armour, Carol L ^a   Taylor, Susan J ^a   Hourihan, Fleur ^a   Smith, Carlene ^a   Krass, Ines ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Community pharmacy; Diabetes; Disease management; Pharmaceutical care; Pharmacy

Indexed keywords

GLYCOSYLATED HEMOGLOBIN;

AGED; ARTICLE; AUSTRALIA; BLOOD; CHEMISTRY; COMPARATIVE STUDY; DISEASE MANAGEMENT; EVALUATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACY; STANDARD; TIME; UTILIZATION REVIEW;

AGED; AUSTRALIA; BLOOD GLUCOSE; COMMUNITY PHARMACY SERVICES; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; TIME FACTORS;

EID: 14644409953     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/1544345041475625     Document Type: Article

References (26)

1. Epstein RS, Sherwood LM. From outcomes research to disease management: a guide for the perplexed. Ann Intern Med. 1996;124:832-7.
2. Amos AF, Zimmet PZ, McCarty DJ. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med. 1997;14: S7-S85.
3. Strand L, Guerrero R, Nickman N, Morley P. Integrated patient-specific model of pharmacy practice. Am J Hosp Pharm. 1990;47:550-4.
4. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990; 47:533-43.
5. Lloyd A. A mere supply role or major contributor. Aust Pharm. 1995;14:549-52.
6. Davidson MB, Karlan VJ, Hair TL. Effect of a pharmacist managed diabetes- care program in a free clinic. Am J Med Qual. 2000;15:137-42.
7. Bradley C. The 12 item well-being questionnaire: origins, current stage of development and availability. Diabetes Care. 2000; 23:875-6.
8. Bradley C, Todd C, Gorton E, et al. The development of an individualized questionnaire to measure the perceived impact of diabetes on quality of life: the ADDQoL. Quality of Life Res. 1999;8:79-91.
9. Svarstad B, Chewning B, Sleath B, Claesson C. The brief medication questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns. 1999;37:113-24.
10. Masood N, Armour CL, Krass I. Identifying potential medication related interventions in type 2 diabetes mellitus: a mechanism for enhanced community pharmacy services. J Soc Admin Pharm. 2002;19:170-9.
11. Gates B, Smith C, Krass IK, Armour CL. Diabetes care in community pharmacy - a focus on training the pharmacist to deliver a specialised service. Aust J Pharm. 200;82: 504-8.
12. Jaber LA, Halapy H, Fernet M, et al. Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother. 1996;30:238-43.
13. Cranor C. Outcomes of the Asheville diabetes care project. Pharmacy Times. 1998:19-24.
14. Cranor CW, Bunting BA, Christensen DB. The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc. 2003;43:173-84.
15. Cranor CW, Christensen DB. The Asheville Project: short-term outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc. 2003;43:149-59.
16. Cranor CW, Christensen DB. The Asheville Project: factors associated with outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc. 2003;43:160-72.
17. Stearne MR, Palmer SL, Hammersley MS, et al. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes - UKPDS 39. BMJ. 1998;317:713-20.
18. Tearne MR, Palmer SL, Hammersley MS, et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes - UKPDS 38. BMJ. 1998;317:703-13.
19. Gray A, Raikou M, McGuire A, et al. on behalf of the United Kingdom Prospective Diabetes Study Group. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). BMJ. 2000; 320:1373-8.
20. Paes AHP, Bakker A, Soe Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care. 1997;20:1512-7.
21. Donnan PT, MacDonald TM, Morris AD. Adherence to oral hypoglycaemic medication in a population of patients with diabetes: a retrospective study. Diabet Med. 2002;19:279-84.
22. Boccuzzi SJ, Wogen J, Fox J, et al. Utilization of oral hypoglycemic agents in a drug-insured U.S. population. Diabetes Care. 2001;24:1411-5.
23. Venturini F, Nichol MB, Sun JCY, et al. Compliance with sulfonylureas in a health maintenance organization: a pharmacy record-base study. Ann Pharmacother. 1999;33:281-8.
24. McNabb WL. Adherence in diabetes: can we define it and can we measure it? Diabetes Care. 1997;20:215-8.
25. Eastman R, Javitt J, Herman W, et al. Model of complications of NIDDM: II Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycaemia. Diabetes Care. 1997;20:735-44.
26. Wagner E, Sandhu N, Newton K, et al. Effect of improved glycemic control on health care costs and utilization. JAMA. 2001;285:182-9.